8-K: Castle Biosciences Raises 2025 Revenue Guidance

Castle Biosciences reported strong Q2 2025 core test volume growth and raised its full-year revenue guidance, despite a slight dip in overall Q2 revenue and profitability metrics.

Summary

• Q2 2025 revenue was $86.2 million, a slight decrease from $87.0 million in Q2 2024.
• Adjusted Revenues for Q2 2025 were $86.2 million, compared to $86.6 million for the same period in 2024.
• Total test reports delivered in Q2 2025 increased 6% to 26,574, from 25,102 in Q2 2024.
• Test reports for core revenue drivers (DecisionDx-Melanoma and TissueCypher) increased 33% over Q2 2024.
• Full-year 2025 revenue guidance was raised to $310-320 million, up from the previous range of $287-297 million.
• Gross margin for Q2 2025 was 77%, and Adjusted Gross Margin was 80%, both lower than the 81% and 83% respectively in Q2 2024.
• Net cash provided by operations in Q2 2025 was $20.8 million, down from $24.0 million in Q2 2024.
• Net income for Q2 2025 was $4.5 million, a decrease from $8.9 million in Q2 2024.
• Adjusted EBITDA for Q2 2025 was $10.4 million, significantly lower than $21.5 million in Q2 2024.
• Cash, cash equivalents, and marketable investment securities totaled $275.9 million as of June 30, 2025.
• The company closed the acquisition of Previse and announced a collaboration and license agreement with SciBase.
• DecisionDx-Melanoma was granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA).
• New research showed DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients.
• A reconsideration request for the Novitas LCD regarding DecisionDx-SCC, which became noncovered effective April 24, 2025, was accepted.
• The IDgenetix test offering was discontinued effective May 2025, impacting Q2 revenue and test volume.

Sentiment

Score: 7

Explanation: The company demonstrated strong underlying test volume growth in its core products and raised its full-year revenue guidance, indicating positive momentum. Strategic acquisitions and FDA designations further enhance its long-term prospects. However, Q2 profitability metrics (net income, Adjusted EBITDA, gross margin) declined year-over-year, and the impact of the Novitas LCD on DecisionDx-SCC and the discontinuation of IDgenetix present near-term challenges.

Positives

• Full-year 2025 revenue guidance was raised to $310-320 million, indicating stronger anticipated financial performance.
• Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased 33% over Q2 2024, demonstrating robust underlying business growth.
• TissueCypher Barretts Esophagus test reports nearly doubled, increasing to 9,170 in Q2 2025 from 4,782 in Q2 2024, showing strong adoption.
• DecisionDx-SCC test reports increased to 4,762 in Q2 2025 from 4,277 in Q2 2024, despite the Novitas LCD becoming effective.
• DecisionDx-Melanoma received FDA Breakthrough Device designation, which could accelerate market access and development.
• New clinical data for DecisionDx-Melanoma showed a 32% reduction in mortality risk, reinforcing its clinical value and potential for increased adoption.
• The company's reconsideration request for the Novitas LCD on DecisionDx-SCC was accepted, indicating ongoing efforts to secure coverage.
• The acquisition of Previse and collaboration with SciBase are expected to support midto long-term value creation and expand offerings in gastroenterology and dermatology.
• Cash, cash equivalents, and marketable investment securities totaled $275.9 million, providing a strong balance sheet to support growth initiatives.
• The CEO, Derek Maetzold, received a Lifetime Achievement Award and was named a Most Admired CEO, reflecting strong leadership and industry recognition.
• The company earned multiple Top Workplaces awards, including a third consecutive national Healthcare Industry Top Workplaces award, indicating a positive internal culture.

Negatives

• Q2 2025 revenue of $86.2 million was slightly down from $87.0 million in Q2 2024.
• Gross margin decreased to 77% (from 81% in Q2 2024) and Adjusted Gross Margin decreased to 80% (from 83% in Q2 2024).
• Net cash provided by operations decreased to $20.8 million (from $24.0 million in Q2 2024).
• Net income decreased to $4.5 million (from $8.9 million in Q2 2024), and net income per share also declined.
• Adjusted EBITDA decreased significantly to $10.4 million (from $21.5 million in Q2 2024).
• The Novitas local coverage determination (LCD) included DecisionDx-SCC as noncovered, effective April 24, 2025, negatively impacting Q2 2025 revenue and test report volume.
• The IDgenetix test offering was discontinued effective May 2025, leading to a significant drop in its test reports (1,027 in Q2 2025 vs. 4,903 in Q2 2024).
• The six months ended June 30, 2025, resulted in a net loss of $21.3 million, compared to a net income of $6.4 million for the same period in 2024, primarily due to a one-time acceleration of amortization expense for IDgenetix.

Risks

• Uncertainty regarding reimbursement for products and subsequent coverage decisions, including the Novitas LCD for DecisionDx-SCC.
• Potential inaccuracies in estimated total addressable markets for products and product candidates.
• Challenges related to expenses, capital requirements, and potential needs for additional financing.
• Risks associated with the anticipated cost, timing, and success of product candidates and new test commercialization.
• Difficulties in successfully integrating new businesses, assets, products, or technologies acquired through acquisitions.
• Impact of macroeconomic events and conditions, such as inflation, labor shortages, liquidity concerns in financial institutions, supply chain disruptions, and geopolitical events.
• Possibility that subsequent study or trial results may contradict earlier findings or not support the discussed benefits of tests.
• Challenges in increasing the future scalability of the TissueCypher Test despite planned equipment and technology infrastructure installations.
• The actual application of tests may not provide the anticipated benefits to patients.
• Newer gastroenterology and mental health franchises may not contribute to long-term financial targets as anticipated.

Future Outlook

The company is raising its full-year 2025 revenue guidance to $310-320 million, reflecting confidence in continued top-line performance and test volume growth. It aims to achieve operating cash flow positivity by the end of 2025 and expects to launch its Atopic Dermatitis pipeline expansion by the end of 2025. Strategic initiatives like the Previse acquisition and SciBase collaboration are anticipated to support midto long-term value creation goals.

Management Comments

• "Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect the clinical value our tests provide to clinicians and their patients."
• "We saw very solid total year-over-year test volume growth in our core revenue drivers, with both DecisionDx-Melanoma and TissueCypher exceeding our volume expectations for the quarter, driving our top-line performance."
• "In alignment with our capital allocation priorities and M&A strategy, we closed the Previse tuck-in acquisition and announced an exciting collaboration and license agreement with SciBase, both of which we believe will support our midto long-term value creation goals."
• "At the same time, we remain deeply focused on execution across our current test portfolio, which we believe positions us well for continued near-term success."
• "Our ability to invest in the future while advancing our core franchises reflects the strength of our growth initiatives and commitment to delivering sustainable value to our stakeholders."

Industry Context

The company operates in the diagnostics industry, focusing on innovative tests for cancer and dermatologic conditions. Its strategic acquisitions (Previse) and collaborations (SciBase) indicate a move towards expanding its multiomics and diagnostic offerings, particularly in gastroenterology and atopic dermatitis, aligning with broader industry trends of personalized medicine and early disease detection. The FDA Breakthrough Device designation for DecisionDx-Melanoma highlights the company's commitment to developing cutting-edge diagnostic tools that address significant unmet clinical needs, potentially setting new standards in patient care pathways.

Comparison to Industry Standards

• DecisionDx-Melanoma's association with a 32% reduction in mortality risk and earlier recurrence detection with lower tumor burden sets a high benchmark for prognostic tests in melanoma, aiming to improve patient survival beyond standard clinical assessment.
• DecisionDx-SCC's expanded utility in predicting metastasis, benefit from adjuvant radiation therapy, and local recurrence risk provides a more comprehensive risk assessment than traditional methods, which often rely solely on clinicopathologic factors.
• TissueCypher's strong independent prediction of progression to high-grade dysplasia or esophageal adenocarcinoma, acknowledged by the AGA Clinical Practice Guideline, positions it as a leading biomarker-based tool for Barrett's esophagus surveillance, potentially improving upon endoscopic surveillance alone.
• The company's focus on developing Advanced Diagnostic Laboratory Tests (ADLTs) approved by CMS and securing positive medical policies across therapeutic areas demonstrates a proactive approach to reimbursement, which is a critical industry standard for diagnostic companies.
• The FDA Breakthrough Device designation for DecisionDx-Melanoma signifies that the test offers a potentially more effective diagnosis for a life-threatening disease, a key indicator of innovation and clinical significance within the medical device industry.

Stakeholder Impact

• Shareholders: Positive impact from raised revenue guidance and strategic growth initiatives, but negative impact from reduced Q2 profitability and the IDgenetix discontinuation.
• Clinicians: Enhanced diagnostic tools (e.g., FDA Breakthrough Device designation for DecisionDx-Melanoma, expanded utility of DecisionDx-SCC) provide better guidance for patient care.
• Patients: Improved diagnostic accuracy and risk stratification for melanoma, SCC, and Barrett's esophagus, potentially leading to earlier detection, tailored treatment, and improved outcomes. New pipeline initiatives in atopic dermatitis aim to address unmet clinical needs.
• Employees: Recognition as a "Top Workplace" indicates a positive work environment and culture.
• Payers: Potential for net annual Medicare healthcare savings of up to approximately $972 million by using DecisionDx-SCC to guide adjuvant radiation therapy decisions. However, the Novitas LCD for DecisionDx-SCC indicates ongoing reimbursement challenges.

Next Steps

• Continue execution across the current test portfolio.
• Advance development of a diagnostic test for atopic dermatitis flares in collaboration with SciBase.
• Achieve operating cash flow positivity by the end of 2025.
• Launch the Atopic Dermatitis pipeline expansion by the end of 2025.
• Pursue coverage through State Biomarker Laws in more than 20 states.
• Optimize commercial team and evolve go-to-market strategy.
• Continue provider education and robust patient advocacy strategy.
• Further build evidentiary support for tests.

Key Dates

Recommendation

While the company demonstrated strong underlying test volume growth in core products and raised its full-year revenue guidance, indicating positive future momentum, the Q2 profitability metrics (net income, Adjusted EBITDA, gross margin) showed a significant year-over-year decline. The impact of the Novitas LCD on DecisionDx-SCC and the discontinuation of IDgenetix introduce near-term headwinds and uncertainty regarding future revenue streams from these specific tests. The strategic acquisitions and FDA designations are positive long-term drivers, but the mixed financial performance in the current quarter suggests a 'hold' position until there is clearer evidence of sustained profitability improvement and successful navigation of reimbursement challenges.

Keywords

Genetic Testing, Oncology, Dermatology, Gastroenterology, Uveal Melanoma, Diagnostic Tests, Precision Medicine, Cancer Diagnostics, Melanoma, Squamous Cell Carcinoma, Barrett's Esophagus, Atopic Dermatitis, Biotechnology, Healthcare, Medical Devices, SEC Filing, Earnings Report, Financial Results, Guidance